The market terminal of cardiovascular drugs in China will break through 150 billion! New drugs continue to drive growth

Source: with the rapid development of global economy and the continuous change of life style, the spectrum of human diseases has changed significantly Cardiovascular disease has become the number one killer threatening human health, and has a huge impact on human life The number of cardiovascular disease patients and the population with cardiovascular risk factors in China is also huge In 2015, the report on nutrition and chronic diseases of Chinese residents issued by the National Center for disease control, the National Cancer Center and the National Cardiovascular Disease Center organized by the national health and Family Planning Commission showed that hypertension and diabetes were the most common chronic diseases, and also the most important risk factors of cardiovascular and cerebrovascular diseases in stroke The prevalence of hypertension and diabetes in China is on the rise In 2012, the prevalence of hypertension in adults aged 18 and over was 25.2% It is estimated that there are 290 million cardiovascular patients in China Experience at home and abroad shows that hypertension and diabetes are preventable and controllable diseases, the key is to find high-risk groups and patients in time, and actively take comprehensive prevention and control measures such as lifestyle intervention During the 12th Five Year Plan period, the awareness rate, treatment rate and control rate of hypertension and diabetes in Chinese residents have been significantly improved, and the rising trend of stroke morbidity and mortality closely related to hypertension and diabetes has been effectively curbed At the same time, the market of cardiovascular drugs in China has been growing rapidly Market growth of 120.98% in the last year of the "12th Five Year Plan" period, the domestic cardiovascular treatment drug market terminal will exceed 150 billion yuan According to the data of China Pharmaceutical Industry Information Center of the Ministry of industry and information technology, in 2014, the cardiovascular purchase amount of sample hospitals in 22 key cities in China was 18.96 billion yuan, an increase of 10.14% over the previous year Under the national strategy of promoting universal health insurance, it is estimated that in 2015, the cardiovascular drug purchase amount of 22 key city sample hospitals will reach 21.565 billion yuan, and the growth rate will reach the normalized value of 13.74% According to the data, during the 11th Five Year Plan period and the 12th Five Year Plan period, the amount of cardiovascular drugs purchased by sample hospitals in 22 key cities increased by 120.98% On the one hand, the awareness rate and diagnosis and treatment rate of cardiovascular diseases have been greatly improved; On the other hand, the level of cardiovascular disease medication has also been improved unprecedentedly, especially the rapid growth of calcium antagonists and renin-a-tensin inhibitors, as well as the rapid growth of statins market, which promotes the development of cardiovascular disease medication market during the 12th Five Year Plan period Statistical analysis shows that: during the 11th Five Year Plan period and the 12th Five Year Plan period, the market of statins in the market of blood lipid regulating drugs has increased by 274%; the market of antihypertensive drugs has increased by 107.95% year on year, of which the growth rate of renin-angiotension inhibitor is 145.14%, and that of calcium channel blocker is 54.60% According to the author's conservative prediction, in the last year of the 12th Five Year Plan period, the domestic cardiovascular treatment drug market terminal will break through the scale of 150 billion yuan The total cost of hospitalization for acute myocardial infarction, intracranial hemorrhage and cerebral infarction, as well as the cost of detection and treatment of cardio cerebral vascular and circulatory system, will keep pace with the cost of cardiovascular drugs In the past 20 years, the market of new drugs in Taiwan during the 13th five year plan has maintained a strong mechanism, This is especially true in the cardiovascular drug market The market growth will continue to be driven by the listing of new drugs According to authoritative data reports, in 2014, the market size of China's drug terminals was 1.28 trillion yuan, an increase of 13.3%, with a year-on-year decrease of 4.1 percentage points It is expected to further decline to 11.5% in 2015, with the overall scale close to RMB 1.43 trillion Analysts predict that in the next three to five years, the growth rate of the drug market will fall to within 10% and become the new normal According to the overall plan of the State Council, by the end of the 13th Five Year Plan period, China's large-scale health medicine industry will reach 8 trillion yuan, double the current scale of 4 trillion yuan; the large-scale health industry has risen to the height of the national development strategy, with huge development space, thus expanding the market of cardiovascular drugs The core factors supporting this space are the change of people's needs and the improvement of health awareness During the 12th Five Year Plan period, people's health concept also changed from disease treatment to prevention and rehabilitation, so the market will have a big breakthrough during the 13th Five Year Plan period Clinical data shows that the cost of disease treatment is much higher than the cost of prevention, and the saving of health expenditure also supports this transformation, so as to promote the development of health industry from medicine to other related fields, expand the market space of health industry, and make the pharmaceutical market get a reasonable development The pharmaceutical treatment industry is a youth industry, and the rigid demand of the pharmaceutical market has maintained a vigorous mechanism in the past 20 years This is especially true in the cardiovascular drug market, where new drugs will continue to drive market growth The cardiovascular new drug market is full of variables In recent years, more cardiovascular drugs have been approved by the FDA of the United States and EMA of Europe Although only a few new drugs have been approved and registered by CFDA, many of them have not been listed in China, but they are still in the 13th five year plan During this period, it will be basically listed in China, such as the cardiovascular drugs, such as clovidipine butyrate, azilsartan ester, lyoxigua, maxitetan, edaxaban, etc., and the new generation of blood lipid regulating drugs, such as alant (alirocumab) and repatha, will have a potential market, thus playing a good part in the "13th five year plan" period.